Skip to content

Iambic Therapeutics

3 viewers · 30d

Total raised

$27.8M

+$27.8M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $27.8M
ROUNDS
1
INVESTORS
7
FOUNDED
N/A
HQ
San Diego, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Iambic Therapeutics is a clinical-stage biopharmaceutical company in San Diego that pairs AI-driven molecular design with automated chemical synthesis and high-throughput experimentation. Its platform combines physics-informed machine learning models with laboratory execution to complete drug design-make-test cycles on a weekly cadence. Iambic advances its own oncology pipeline of brain-penetrant small-molecule inhibitors and also licenses the platform to pharmaceutical partners including Bayer and Revolution Medicines. Its lead candidate moved from program initiation into human trials in roughly two years.

What sets it apart

Physics-informed AI architectures (NeuralPLexer for protein-ligand co-folding, Enchant for multimodal property prediction) tightly coupled to automated synthesis, allowing weekly design-make-test cycles and dramatically compressed timelines from program start to clinical trials.

Funding history

1 round
EquityApr 1, 2026
Form D
+$27.8M$27.8M total

Latest SEC filings

via EDGAR · CIK 0001997038
Form D · Apr 1, 2026View on EDGAR

Products

1 tracked

Iambic AI drug discovery platform (Enchant and NeuralPLexer)

AI drug discovery platform

An AI platform for small-molecule drug design built around two core models: NeuralPLexer, a co-folding model for predicting protein and protein-ligand structures, and Enchant, a multimodal transformer for predicting molecular properties. The models are integrated with automated chemical synthesis and experimental execution so novel designs are turned into biological data each week.

  • NeuralPLexer co-folding model for protein and protein-ligand structure prediction
  • Enchant multimodal transformer for molecular property prediction
  • Physics principles embedded in the AI architecture for data efficiency
  • Automated chemical synthesis integrated with high-throughput experimentation